Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2002;106:679-684
Published online before print July 15, 2002, doi: 10.1161/01.CIR.0000025403.20953.23
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
106/6/679    most recent
01.CIR.0000025403.20953.23v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haffner, S. M.
Right arrow Articles by Freed, M. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haffner, S. M.
Right arrow Articles by Freed, M. I.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetes
Related Collections
Right arrow Type 2 diabetes
Right arrow Risk Factors

(Circulation. 2002;106:679.)
© 2002 American Heart Association, Inc.


Clinical Investigation and Reports

Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus

Steven M. Haffner, MD; Andrew S. Greenberg, MD; Wayde M. Weston, PhD; Hongzi Chen, PhD; Ken Williams, MS; Martin I. Freed, MD

From University of Texas Health Science Center at San Antonio (S.M.H., K.W.), San Antonio, Tex; Tufts-New England Medical Center (A.S.G.), Boston, Mass; and GlaxoSmithKline (W.M.W., H.C., M.I.F.), Collegeville, Philadelphia, Pa.

Correspondence to Steven M. Haffner, MD, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, MC 7873, San Antonio, TX 78229-3900. E-mail haffner{at}uthscsa.edu

Background Markers of systemic inflammation (eg, C-reactive protein [CRP] and interleukin-6 [IL-6]) have been proposed to be "nontraditional" risk factors for cardiovascular disease in patients with type 2 diabetes mellitus. Matrix metalloproteinase-9 (MMP-9) has been implicated in the pathogenesis of atherosclerotic plaque rupture, which raises the possibility of the use of MMP-9 levels as a marker for future myocardial infarction or unstable angina. In vitro and animal studies suggest that thiazolidinediones can reduce the expression of these markers. The purpose of this analysis was to determine whether rosiglitazone alters serum concentrations of CRP, IL-6, MMP-9, and white blood cell count (WBC) and to examine the relationship of these effects with demographic and disease variables.

Methods and Results CRP, IL-6, MMP-9, and WBC were analyzed from stored frozen serum samples obtained from patients with type 2 diabetes who completed a 26-week randomized, double-blind, placebo-controlled study. After 26 weeks of rosiglitazone treatment, the percentage reductions in mean CRP, MMP-9, and WBC levels were statistically significant compared with baseline and placebo (P<0.01). The percentage reduction in mean IL-6 was small and similar in the rosiglitazone and placebo groups. The change in each inflammatory marker from baseline to week 26 was significantly correlated (P<0.05) with each of the other markers, as well as with the homeostasis model assessment estimate of insulin resistance.

Conclusions Rosiglitazone reduces serum levels of MMP-9 and the proinflammatory marker CRP in patients with type 2 diabetes, which indicates potentially beneficial effects on overall cardiovascular risk.


Key Words: atherosclerosis • cardiovascular diseases • diabetes mellitus • inflammation • risk factors




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
G. Orasanu, O. Ziouzenkova, P. R. Devchand, V. Nehra, O. Hamdy, E. S. Horton, and J. Plutzky
The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-{alpha}-Dependent Manner In Vitro and In Vivo in Mice
J. Am. Coll. Cardiol., July 2, 2008; (2008) j.jacc.2008.04.055v1.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. K. McGuire and S. E. Inzucchi
New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications
Circulation, January 22, 2008; 117(3): 440 - 449.
[Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
T. M. Wolever, A. L Gibbs, C. Mehling, J.-L. Chiasson, P. W Connelly, R. G Josse, L. A Leiter, P. Maheux, R. Rabasa-Lhoret, N W. Rodger, et al.
The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein
Am. J. Clinical Nutrition, January 1, 2008; 87(1): 114 - 125.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
L. L. Lipscombe, T. Gomes, L. E. Levesque, J. E. Hux, D. N. Juurlink, and D. A. Alter
Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes
JAMA, December 12, 2007; 298(22): 2634 - 2643.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
C.-C. Fang, Yeun Tarl Fresner Ng Jao, Yi-Chen, C.-L. Yu, C.-L. Chen, and S.-P. Wang
Angiographic and Clinical Outcomes of Rosiglitazone in Patients With Type 2 Diabetes Mellitus After Percutaneous Coronary Interventions: A Single Center Experience
Angiology, November 1, 2007; 58(5): 523 - 534.
[Abstract] [PDF]


Home page
Vasc MedHome page
A. S. Kelly, A. M. Thelen, D. R. Kaiser, J. M. Gonzalez-Campoy, and A. J. Bank
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
Vascular Medicine, November 1, 2007; 12(4): 311 - 318.
[Abstract] [PDF]


Home page
J. Nutr.Home page
H. Shen, R. MacDonald, D. Bruemmer, A. Stromberg, A. Daugherty, X.-a. Li, M. Toborek, and B. Hennig
Zinc Deficiency Alters Lipid Metabolism in LDL Receptor Deficient Mice Treated with Rosiglitazone
J. Nutr., November 1, 2007; 137(11): 2339 - 2345.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
B. Gustafson, A. Hammarstedt, C. X. Andersson, and U. Smith
Inflamed Adipose Tissue: A Culprit Underlying the Metabolic Syndrome and Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2276 - 2283.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Cardiovascular DiseaseHome page
C. Schindler
Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?
Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 7 - 26.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Z. Berberoglu, A. Gursoy, N. Bayraktar, A. C. Yazici, N. Bascil Tutuncu, and N. Guvener Demirag
Rosiglitazone Decreases Serum Bone-Specific Alkaline Phosphatase Activity in Postmenopausal Diabetic Women
J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3523 - 3530.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
N. P.E. Kadoglou, F. Iliadis, C. D. Liapis, D. Perrea, N. Angelopoulou, and M. Alevizos
Beneficial Effects of Combined Treatment With Rosiglitazone and Exercise on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
Diabetes Care, September 1, 2007; 30(9): 2242 - 2244.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. Momin, N. Melikian, S. B. Wheatcroft, D. Grieve, L. C. John, A. El Gamel, M. T. Marrinan, J. B. Desai, C. Driver, R. Sherwood, et al.
The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery
J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 335 - 341.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
P. Hollander, D. Yu, and H. S. Chou
Low-Dose Rosiglitazone in Patients With Insulin-Requiring Type 2 Diabetes
Arch Intern Med, June 25, 2007; 167(12): 1284 - 1290.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Fischoeder, H. Meyborg, D. Stibenz, E. Fleck, K. Graf, and P. Stawowy
Insulin augments matrix metalloproteinase-9 expression in monocytes
Cardiovasc Res, March 1, 2007; 73(4): 841 - 848.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. D. Brown and J. Plutzky
Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Circulation, January 30, 2007; 115(4): 518 - 533.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
C.-K. Chiang, T.-I. Ho, Y.-S. Peng, S.-P. Hsu, M.-F. Pai, S.-Y. Yang, K.-Y. Hung, and K.-D. Wu
Rosiglitazone in Diabetes Control in Hemodialysis Patients With and Without Viral Hepatitis Infection: Effectiveness and side effects
Diabetes Care, January 1, 2007; 30(1): 3 - 7.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
T. Mazzone, P. M. Meyer, S. B. Feinstein, M. H. Davidson, G. T. Kondos, R. B. D'Agostino Sr, A. Perez, J.-C. Provost, and S. M. Haffner
Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial
JAMA, December 6, 2006; 296(21): 2572 - 2581.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
P. Germain, B. Staels, C. Dacquet, M. Spedding, and V. Laudet
Overview of Nomenclature of Nuclear Receptors
Pharmacol. Rev., December 1, 2006; 58(4): 685 - 704.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
G. M. Howard-Alpe, J. W. Sear, and P. Foex
Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of biochemical markers
Br. J. Anaesth., December 1, 2006; 97(6): 758 - 769.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
K. ALEXANDRAKI, C. PIPERI, C. KALOFOUTIS, J. SINGH, A. ALAVERAS, and A. KALOFOUTIS
Inflammatory Process in Type 2 Diabetes: The Role of Cytokines
Ann. N.Y. Acad. Sci., November 1, 2006; 1084(1): 89 - 117.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Kapiotis, G. Holzer, G. Schaller, M. Haumer, H. Widhalm, D. Weghuber, B. Jilma, G. Roggla, M. Wolzt, K. Widhalm, et al.
A Proinflammatory State Is Detectable in Obese Children and Is Accompanied by Functional and Morphological Vascular Changes
Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2541 - 2546.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Libby and P. M. Ridker
Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A33 - A46.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. Ahmed, C. P. Cannon, S. A. Murphy, and E. Braunwald
Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
Eur. Heart J., October 1, 2006; 27(19): 2323 - 2329.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. E. Feldon, C. W. O'Loughlin, D. M. Ray, S. Landskroner-Eiger, K. E. Seweryniak, and R. P. Phipps
Activated Human T Lymphocytes Express Cyclooxygenase-2 and Produce Proadipogenic Prostaglandins that Drive Human Orbital Fibroblast Differentiation to Adipocytes
Am. J. Pathol., October 1, 2006; 169(4): 1183 - 1193.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. Ghanim, S. Dhindsa, A. Aljada, A. Chaudhuri, P. Viswanathan, and P. Dandona
Low-Dose Rosiglitazone Exerts an Antiinflammatory Effect with an Increase in Adiponectin Independently of Free Fatty Acid Fall and Insulin Sensitization in Obese Type 2 Diabetics
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3553 - 3558.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Shadid, C. D. A. Stehouwer, and M. D. Jensen
Diet/Exercise Versus Pioglitazone: Effects of Insulin Sensitization with Decreasing or Increasing Fat Mass on Adipokines and Inflammatory Markers
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3418 - 3425.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. E. Kahn, B. Zinman, S. M. Haffner, M. C. O'Neill, B. G. Kravitz, D. Yu, M. I. Freed, W. H. Herman, R. R. Holman, N. P. Jones, et al.
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.
Diabetes, August 1, 2006; 55(8): 2357 - 2364.
[Abstract] [Full Text] [PDF]


Home page
Clin. DiabetesHome page
M. Blaha and T. A. Elasy
Clinical Use of the Metabolic Syndrome: Why the Confusion?
Clin. Diabetes, July 1, 2006; 24(3): 125 - 131.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. Marfella, M. D'Amico, C. Di Filippo, A. Baldi, M. Siniscalchi, F. C. Sasso, M. Portoghese, O. Carbonara, B. Crescenzi, P. Sangiuolo, et al.
Increased Activity of the Ubiquitin-Proteasome System in Patients With Symptomatic Carotid Disease Is Associated With Enhanced Inflammation and May Destabilize the Atherosclerotic Plaque: Effects of Rosiglitazone Treatment
J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2444 - 2455.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
K. Esposito, M. Ciotola, D. Carleo, B. Schisano, F. Saccomanno, F. C. Sasso, D. Cozzolino, R. Assaloni, D. Merante, A. Ceriello, et al.
Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome
Diabetes Care, May 1, 2006; 29(5): 1071 - 1076.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
A. I. Vinik, J. Ullal, H. K. Parson, P. M. Barlow, and C. M. Casellini
Pioglitazone Treatment Improves Nitrosative Stress in Type 2 Diabetes
Diabetes Care, April 1, 2006; 29(4): 869 - 876.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F. Meisner, D. Walcher, F. Gizard, X. Kapfer, R. Huber, A. Noak, L. Sunder-Plassmann, H. Bach, C. Haug, M. Bachem, et al.
Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients: Data From a Randomized Placebo-Controlled Trial
Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 845 - 850.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
R. Marfella, M. D'Amico, K. Esposito, A. Baldi, C. Di Filippo, M. Siniscalchi, F. C. Sasso, M. Portoghese, F. Cirillo, F. Cacciapuoti, et al.
The Ubiquitin-Proteasome System and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Rosiglitazone Treatment
Diabetes, March 1, 2006; 55(3): 622 - 632.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
G. D. Barish
Peroxisome Proliferator-Activated Receptors and Liver X Receptors in Atherosclerosis and Immunity
J. Nutr., March 1, 2006; 136(3): 690 - 694.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F. F. Samaha, P. O. Szapary, N. Iqbal, M. M. Williams, L. T. Bloedon, A. Kochar, M. L. Wolfe, and D. J. Rader
Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients With Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome
Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 624 - 630.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
R. Agarwal
Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy
Am J Physiol Renal Physiol, March 1, 2006; 290(3): F600 - F605.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F. Blaschke, Y. Takata, E. Caglayan, R. E. Law, and W. A. Hsueh
Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes
Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 28 - 40.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. O. Szapary, L. T. Bloedon, F. F. Samaha, D. Duffy, M. L. Wolfe, D. Soffer, M. P. Reilly, J. Chittams, and D. J. Rader
Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome
Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 182 - 188.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. K. Koh, S. H. Han, and M. J. Quon
Inflammatory Markers and the Metabolic Syndrome: Insights From Therapeutic Interventions
J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1978 - 1985.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
U. Singh, J. Tabibian, S. K. Venugopal, S. Devaraj, and I. Jialal
Development of an In Vitro Screening Assay to Test the Antiinflammatory Properties of Dietary Supplements and Pharmacologic Agents
Clin. Chem., December 1, 2005; 51(12): 2252 - 2256.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. W.F. Wilson, R. B. D'Agostino, H. Parise, L. Sullivan, and J. B. Meigs
Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus
Circulation, November 15, 2005; 112(20): 3066 - 3072.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
N. Marx, J. Wohrle, T. Nusser, D. Walcher, A. Rinker, V. Hombach, W. Koenig, and M. Hoher
Pioglitazone Reduces Neointima Volume After Coronary Stent Implantation: A Randomized, Placebo-Controlled, Double-Blind Trial in Nondiabetic Patients
Circulation, November 1, 2005; 112(18): 2792 - 2798.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. K. Ray, C. P. Cannon, R. Cairns, D. A. Morrow, N. Rifai, A. J. Kirtane, C. H. McCabe, A. M. Skene, C. M. Gibson, P. M. Ridker, et al.
Relationship Between Uncontrolled Risk Factors and C-Reactive Protein Levels in Patients Receiving Standard or Intensive Statin Therapy for Acute Coronary Syndromes in the PROVE IT-TIMI 22 Trial
J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1417 - 1424.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
2nd International Symposium on Triglycerides and HDL: Metabolic syndrome
Diabetes Care, October 1, 2005; 28(10): 2577 - 2584.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Calabro, D. W. Chang, J. T. Willerson, and E. T.H. Yeh
Release of C-Reactive Protein in Response to Inflammatory Cytokines by Human Adipocytes: Linking Obesity to Vascular Inflammation
J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1112 - 1113.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
J. P.H. van Wijk, E. J.P. de Koning, M. C. Cabezas, J. op't Roodt, J. Joven, T. J. Rabelink, and A. I. Hoepelman
Comparison of Rosiglitazone and Metformin for Treating HIV Lipodystrophy: A Randomized Trial
Ann Intern Med, September 6, 2005; 143(5): 337 - 346.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
A Consoli and E Devangelio
Thiazolidinediones and inflammation
Lupus, September 1, 2005; 14(9): 794 - 797.
[Abstract] [PDF]


Home page
Diabetes CareHome page
R. Kahn, J. Buse, E. Ferrannini, and M. Stern
The Metabolic Syndrome: Time for a Critical Appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care, September 1, 2005; 28(9): 2289 - 2304.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
Inflammation, Atherosclerosis, and Aspects of Insulin Action
Diabetes Care, September 1, 2005; 28(9): 2312 - 2319.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Dhindsa, D. Tripathy, N. Sanalkumar, S. Ravishankar, H. Ghanim, A. Aljada, and P. Dandona
Free Fatty Acid-Induced Insulin Resistance in the Obese Is Not Prevented by Rosiglitazone Treatment
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5058 - 5063.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Hetzel, B. Balletshofer, K. Rittig, D. Walcher, W. Kratzer, V. Hombach, H.-U. Haring, W. Koenig, and N. Marx
Rapid Effects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers
Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1804 - 1809.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
Second World Congress on the Insulin Resistance Syndrome: Hypertension, cardiovascular disease, and treatment approaches
Diabetes Care, August 1, 2005; 28(8): 2073 - 2080.
[Full Text] [PDF]


Home page
DiabetesHome page
B. Staels and J.-C. Fruchart
Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists
Diabetes, August 1, 2005; 54(8): 2460 - 2470.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
I. Tarkun, B. Cetinarslan, E. Turemen, T. Sahin, Z. Canturk, and B. Komsuoglu
Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome
Eur. J. Endocrinol., July 1, 2005; 153(1): 115 - 121.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
S. E. Inzucchi, F. A. Masoudi, Y. Wang, M. Kosiborod, J. M. Foody, J. F. Setaro, E. P. Havranek, and H. M. Krumholz
Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction: Insights from the National Heart Care Project
Diabetes Care, July 1, 2005; 28(7): 1680 - 1689.